The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).
P Kleiblová, J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl
{"title":"The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).","authors":"P Kleiblová, J Novotný, D Cibula, V Curtisová, O Dubová, L Foretová, A Germanová, M Janatová, O Havránek, M Hojsáková, M Hudcová, M Koudová, V Krutílková, M Palacova, S Paulich, K Petrakova, J Presl, A Puchmajerová, J Soukupová, M Šenkeříková, Z Šimková, H Štěpánková, I Šubrt, I Tachecí, P Tesner, O Urban, K Veselá, Š Vilímová, Z Vlčková, M Vočka, V Weinberger, M Zikán, M Zimovjanová, Z Kleibl","doi":"10.48095/ccko2024292","DOIUrl":null,"url":null,"abstract":"<p><p>The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48095/ccko2024292","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.
临床相关癌症易感基因致病变异携带者临床实践指南》规定了捷克共和国应为这些遗传性癌症高危人群提供的一级和二级预防措施。该指南由捷克医学会 J. E. Purkyně 医学遗传学和基因组学学会肿瘤遗传学工作组（SLG ČLS JEP）与肿瘤学和妇科肿瘤学代表合作起草。该指南以美国国家综合癌症网络（NCCN）和欧洲肿瘤内科学会（ESMO）的现行建议为基础，并考虑了捷克医疗保健系统的能力。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
